Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Gastric pentadecapeptide with broad tissue-healing properties.
Peptide B
Healing & Recovery
Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity.
Typical vial
5 mg
Typical dose
250-500 mcg
Half-life
~4 hours (estimated from animal pharmacokinetic data)
FDA status
Not FDA approved for human use. FDA issued a warning letter …
Typical vial
5 mg
Typical dose
50-100 mcg
Half-life
~15-30 minutes (rapidly degraded by proteases)
FDA status
Not FDA approved for human use.
BPC-157 effects
LL-37 effects
BPC-157 side effects
LL-37 side effects
BPC-157 dosing ranges
General tissue repair
250-500 mcg · Once or twice daily · 4-6 weeks
Gut healing
250-500 mcg · Twice daily (oral or SubQ) · 4-8 weeks
Acute injury recovery
500 mcg · Twice daily near injury site · 2-4 weeks
LL-37 dosing ranges
Antimicrobial support
50-100 mcg · Once daily (SubQ) · 2-4 weeks
Wound healing support
50-100 mcg · Once daily near affected area · 2-4 weeks
BPC-157: Gastric pentadecapeptide with broad tissue-healing properties. Typical dose 250-500 mcg. LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. Both fall under the Healing & Recovery category.
Stacking BPC-157 with LL-37 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
BPC-157 is typically dosed: Once or twice daily for General tissue repair; Twice daily (oral or SubQ) for Gut healing; Twice daily near injury site for Acute injury recovery. LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support.
BPC-157: Not FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products. LL-37: Not FDA approved for human use.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free